Xinhua Silk Road: E. China's Wuxi city steps up biomedical industry development

Xinhua Silk Road

PR97364

 

BEIJING, Aug. 8, 2022 /PRNewswire=KYODO JBN/ --

 

The 2022 Taihu Bay Future Healthcare Conference held Thursday in Wuxi City in

east China's Jiangsu Province witnessed the launch of Wuxi Intellectual

Property Protection Center with 52 biomedical projects contracted, involving a

total of more than 30 billion yuan investment.

 

Biomedical industry is an important part of Wuxi's modern industrial system

construction during the 14th Five-Year Plan(2021-2025) period. Its scale topped

140 billion yuan in 2021, a year-on-year increase of 24 percent, making Wuxi

among the top 20 prefecture-level cities listed in China Biomedical Industry

Barometer in 2021.

 

Besides the property protection center, six biomedical industrial parks were

licensed and three biomedical public platforms were inaugurated at the

conference, which are expected to inject impetus to the development of Wuxi's

biomedical industry.

 

The city will strengthen and expand its industrial chain to build a

200-billion-yuan modern biomedical industrial cluster, said Du Xiaogang,

Secretary of the Wuxi Municipal Party Committee of CPC.

 

The biomedical industry started early in Wuxi. With good foundation, it has

developed a relatively comp industry chain covering chemical raw medicine

production, preparation production, and pharmaceutical service outsourcing, and

gathered 1,278 biomedical companies such as AstraZeneca and WuXi Biologics

AppTech, showing strong clustering effect.

 

Aiming at building a world-class biomedical industry highland with distinctive

characteristics, Wuxi not only issued a special policy tailored for the

development of biomedical industrial parks, but also established a special fund

for modern biomedical industry to reward breakthrough in the forward-looking

technologies and innovation research. In 2021, Wuxi funded more than 32 million

yuan for the science and technology development of 43 biomedical projects.

 

Multiple fund agreements were signed at the conference, including a biomedical

fund of 5 billion yuan jointly established by Guolian Group, AstraZeneca, and

China International Capital Corporation Limited.

 

Original link: https://en.imsilkroad.com/p/329376.html

 

Source Xinhua Silk Road

 

Image Attachments Links:

 

   Link: http://asianetnews.net/view-attachment?attach-id=427118

 

   Caption: Photo shows 2022 Taihu Bay Future Healthcare Conference site

 

 

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中